{"entity":{"id":"nct02739594","kind":"trial","name":"Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma","aka":["COMPARE"],"tldr":"A phase 3 trial of Ibandronic acid and Zoledronic acid in Multiple myeloma, run by Hoffmann-La Roche, recorded as terminated on the registry.","summary":"Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma is a phase 3 interventional study registered as NCT02739594 by Hoffmann-La Roche, with 89 participants recorded, started 2006-02 and due to reach its primary completion in 2009-04. Interventions recorded: Ibandronate, Zoledronate. Conditions recorded: Multiple Myeloma.\n\nLinked to the drug Ibandronic acid because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02739594","url":"https://clinicaltrials.gov/study/NCT02739594"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["ibandronic-acid","zoledronic-acid"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02739594","phase":"3","setting":"COMPARE: Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Patients With Multiple Myeloma","sponsor":"Hoffmann-La Roche","started":"2006-02","yearReported":2016,"enrolled":89,"enrolledBasis":"registry","outcomes":[{"endpoint":"Percentage of Participants With Deterioration in Renal Function According to Reduction in Creatinine Clearance (CrCl) From Baseline to Week 44","primary":true,"unit":"%","arms":[{"name":"Ibandronate","n":41,"value":9.8,"note":"95% CI 2.7 to 23.1; Figures from the ClinicalTrials.gov results section (first posted 2016-07-22), not from a publication"},{"name":"Zoledronate","n":40,"value":12.5,"note":"95% CI 4.2 to 26.8"}],"source":"https://clinicaltrials.gov/study/NCT02739594?tab=results"}]},"route":"/trials/nct02739594/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"ibandronic-acid","kind":"drug","name":"Ibandronic acid","route":"/drugs/ibandronic-acid/"},{"id":"zoledronic-acid","kind":"drug","name":"Zoledronic acid","route":"/drugs/zoledronic-acid/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}]}}